TWI692448B - Drinking and soothing system for lowering blood sugar - Google Patents
Drinking and soothing system for lowering blood sugar Download PDFInfo
- Publication number
- TWI692448B TWI692448B TW106113286A TW106113286A TWI692448B TW I692448 B TWI692448 B TW I692448B TW 106113286 A TW106113286 A TW 106113286A TW 106113286 A TW106113286 A TW 106113286A TW I692448 B TWI692448 B TW I692448B
- Authority
- TW
- Taiwan
- Prior art keywords
- container
- drinking water
- energy
- ring
- weight ratio
- Prior art date
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 35
- 239000008280 blood Substances 0.000 title claims abstract description 35
- 230000035622 drinking Effects 0.000 title claims abstract description 12
- 239000000463 material Substances 0.000 claims abstract description 56
- 229910052720 vanadium Inorganic materials 0.000 claims abstract description 54
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 claims abstract description 54
- 239000003651 drinking water Substances 0.000 claims abstract description 53
- 235000020188 drinking water Nutrition 0.000 claims abstract description 53
- 230000002218 hypoglycaemic effect Effects 0.000 claims abstract description 38
- 238000003756 stirring Methods 0.000 claims abstract description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 239000012530 fluid Substances 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 10
- 229910052613 tourmaline Inorganic materials 0.000 claims description 9
- 229940070527 tourmaline Drugs 0.000 claims description 9
- 239000011032 tourmaline Substances 0.000 claims description 9
- 230000005540 biological transmission Effects 0.000 claims description 8
- 230000007246 mechanism Effects 0.000 claims description 8
- 239000007921 spray Substances 0.000 claims description 6
- 230000010030 glucose lowering effect Effects 0.000 claims description 5
- 239000011229 interlayer Substances 0.000 claims description 5
- 239000011230 binding agent Substances 0.000 claims description 4
- 230000035939 shock Effects 0.000 claims description 3
- 238000005507 spraying Methods 0.000 claims description 3
- 238000013019 agitation Methods 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 17
- 208000024891 symptom Diseases 0.000 abstract description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 10
- 239000008103 glucose Substances 0.000 description 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- 238000011282 treatment Methods 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 239000011777 magnesium Substances 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 2
- 102000004338 Transferrin Human genes 0.000 description 2
- 108090000901 Transferrin Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 102000030621 adenylate cyclase Human genes 0.000 description 2
- 108060000200 adenylate cyclase Proteins 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000002308 calcification Effects 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 208000002925 dental caries Diseases 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000003116 impacting effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 235000019626 lipase activity Nutrition 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000011866 long-term treatment Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 229940126701 oral medication Drugs 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 239000012581 transferrin Substances 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- LSGOVYNHVSXFFJ-UHFFFAOYSA-N vanadate(3-) Chemical compound [O-][V]([O-])([O-])=O LSGOVYNHVSXFFJ-UHFFFAOYSA-N 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 241000208340 Araliaceae Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- -1 adenylase Proteins 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 108091005995 glycated hemoglobin Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 239000000864 hyperglycemic agent Substances 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical group [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000007410 oral glucose tolerance test Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
Images
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本發明揭露一種降血糖的飲用舒緩系統,其包括容器、降血糖能量材料、機座及能量衝擊單元。容器可供飲用水容置其內。降血糖能量材料包含佔重比約為2~15百分比的釩材料,降血糖能量材料浸泡於容器內的飲用水中。機座頂部可供容器置放。能量衝擊單元設置用以對飲用水進行攪動衝擊,使降血糖能量材料在攪動衝擊下有效地將釩元素及能量元素釋出於飲用水之中,俾能有效降低糖尿病血糖,以緩解糖尿病所帶來的不適症狀。 The invention discloses a drinking and soothing system for lowering blood sugar, which includes a container, a blood sugar lowering energy material, a machine base and an energy impact unit. The container can contain drinking water. The hypoglycemic energy material contains vanadium material with a weight ratio of about 2 to 15%, and the hypoglycemic energy material is immersed in drinking water in a container. The top of the base can be used for container placement. The energy impact unit is set to stir the drinking water, so that the hypoglycemic energy material can effectively release the vanadium element and the energy element into the drinking water under the stirring impact, so as to effectively reduce the blood sugar of diabetes and relieve the diabetes Discomfort symptoms.
Description
本發明係有關一種降血糖的飲用舒緩系統,尤指一種可以有效降低血糖以緩解糖尿病所帶來不適症狀的血糖舒緩技術。 The invention relates to a drinking and soothing system for lowering blood sugar, in particular to a blood sugar soothing technology that can effectively lower blood sugar to relieve the discomfort symptoms caused by diabetes.
按,糖尿病是一種嚴重性的新陳代謝疾病。當人體內的胰島素分泌不足時,葡萄糖則無法進入細胞內被利用,以致血液中的葡萄糖含量增加,因而引起內分泌的代謝失調。根據美國糖尿病協會的認定標準,滿足以下任一條件,即可診斷為糖尿病:1.空腹血漿血糖在7.0毫摩爾/升(126毫克/分升)或以上;2.在口服糖耐量試驗中,口服75克葡萄糖2小時後,血漿血糖在11.1毫摩爾/升(200毫克/分升)或以上;3.有高血糖病徵,並且隨機血漿血糖在11.1毫摩爾/升(200毫克/分升)或以上;4.糖化血紅蛋白(HbA1C)在6.5或以上。倘若人體血糖過高,葡萄糖則無法完全被腎臟所吸收,以致葡萄糖會隨著尿液排出,當尿液含有大量的糖分時,則是所謂的糖尿病。 Pressed, diabetes is a serious metabolic disease. When there is insufficient insulin secretion in the body, glucose cannot enter the cells and be utilized, so that the glucose content in the blood increases, thus causing endocrine metabolic disorders. According to the certification criteria of the American Diabetes Association, diabetes can be diagnosed by satisfying any of the following conditions: 1. Fasting plasma glucose is 7.0 mmol/L (126 mg/dL) or above; 2. In the oral glucose tolerance test, After 2 hours of oral administration of 75 grams of glucose, the plasma glucose is 11.1 mmol/L (200 mg/dl) or more; 3. There are symptoms of hyperglycemia, and the random plasma glucose is 11.1 mmol/L (200 mg/dl) Or above; 4. Glycated hemoglobin (HbA1C) is 6.5 or above. If the body's blood sugar is too high, glucose cannot be completely absorbed by the kidneys, so that glucose will be excreted with urine. When urine contains a lot of sugar, it is called diabetes.
目前西醫用於治療糖尿病的方法大致有二種,第一種是以注射方式補充胰島素。第二種則是以口服藥物的方式來控制血糖。雖然上述治療方法皆可促進胰島素的分泌或是降低胰島素的抗性,藉以控制病患的糖尿病之高血糖因子,惟,上述治療方法僅能控制糖尿病的血糖而無法根治,倘若停止注射胰島素或口服藥物治療時,則會引發諸多的併發症出現,不僅如此,上述治療方法為一種侵入式的對抗療法,因此,在長期治療之 下,較容易傷及腎臟,終致造成洗腎的憾事。中醫治療糖尿病的方面,如中華民國發明第I356706『可控制代謝症候群之中草藥組成物』專利所示,其係由咸豐草與人蔘組成,具有促進胰島素分泌與降低胰島素抗性的作用,雖然該習用治療方法可以調節人體血糖值,惟,其仍然是屬於口服藥物治療的一種,故可將其視為廣義的間接侵入性治療,因為其所發揮出的藥性仍會對人體產生約束(Chemical Restraint)作用,因此,在長期服用治療之下,同樣容易傷及腎臟器官。 At present, there are roughly two methods for Western medicine to treat diabetes. The first is to supplement insulin by injection. The second is to control blood sugar by oral medication. Although the above treatments can promote the secretion of insulin or reduce insulin resistance to control the hyperglycemic factors of diabetes in patients, the above treatments can only control the blood sugar of diabetes and cannot be cured, if the injection of insulin or oral administration is stopped During drug treatment, many complications will occur. Not only that, but the above treatment is an invasive confrontation therapy. Therefore, under long-term treatment, it is more likely to damage the kidneys and eventually cause regrets for kidney dialysis. As regards the treatment of diabetes by traditional Chinese medicine, as shown in the patent of the Republic of China Invention No. I356706 "Chinese Herbal Compositions with Controllable Metabolic Syndrome", it is composed of Xianfeng grass and ginseng and has the effect of promoting insulin secretion and reducing insulin resistance, although the Conventional treatment methods can adjust the blood sugar level of the human body, but it is still a type of oral drug therapy, so it can be regarded as a generalized indirect invasive treatment, because the drug properties it exerts will still constrain the human body (Chemical Restraint ) Function, therefore, under long-term treatment, it is also easy to damage the kidneys.
迄今為止,仍無一種可以模擬水受到自然環境攪動衝擊而有效釋出各種能量元素及釩元素的飲用舒緩技術的論文被發表或是專利的提出,有鑑於此,上述習知技術確實未臻完善仍有再改善的必要性,於是,經本發明人等不斷努力研發下,終於研發出可以改善習知技術缺失的本發明。 So far, there is no paper that can simulate the drinking and soothing technology that can effectively release various energy elements and vanadium elements due to the agitation of the natural environment. The above-mentioned conventional technology has not been perfected in view of this. There is still a need for further improvement. Therefore, through continuous efforts by the inventors and others, the present invention has finally been developed that can improve the lack of conventional technology.
本發明第一目的,在於提供一種可以有效降低血糖的飲用舒緩系統,主要是藉由攪動或衝擊作用使浸泡飲用水可以釋出多種能量元素及釩元素,除了可以達到身體保健功效之外,並可有效降低血糖而達到緩解糖尿病所帶來的不適症狀。達成本發明第一目的採用之技術手段,係包括容器、降血糖能量材料、機座及能量衝擊單元。容器可供飲用水容置其內。降血糖能量材料包含佔重比約為2~15百分比的釩材料,降血糖能量材料浸泡於容器內的飲用水中。機座頂部可供容器置放。能量衝擊單元設置用以對飲用水進行攪動衝擊,使降血糖能量材料在攪動衝擊下有效地將釩元素及能量元素釋出於飲用水之中。 The first object of the present invention is to provide a drinking and soothing system that can effectively lower blood sugar, mainly by stirring or impacting the soaked drinking water to release a variety of energy elements and vanadium elements, in addition to achieving body health benefits, and It can effectively lower blood sugar and relieve the discomfort symptoms caused by diabetes. The technical means adopted to achieve the first object of the invention include a container, a hypoglycemic energy material, a base and an energy impact unit. The container can contain drinking water. The hypoglycemic energy material contains vanadium material with a weight ratio of about 2 to 15%, and the hypoglycemic energy material is immersed in drinking water in a container. The top of the base can be used for container placement. The energy impact unit is provided to stir and impact the drinking water, so that the hypoglycemic energy material can effectively release the vanadium element and the energy element from the drinking water under the stirring impact.
本發明第二目的,在於提供一種可以模擬水受到自然環境攪 動衝擊而有效釋出各種能量元素及釩元素的降血糖飲用舒緩系統。達成本發明第二目的採用之技術手段,係包括容器、降血糖能量材料、機座及能量衝擊單元。容器可供飲用水容置其內。降血糖能量材料包含佔重比約為2~15百分比的釩材料,降血糖能量材料浸泡於容器內的飲用水中。機座頂部可供容器置放。能量衝擊單元設置用以對飲用水進行攪動衝擊,使降血糖能量材料在攪動衝擊下有效地將釩元素及能量元素釋出於飲用水之中。其中,該能量衝擊單元更包含一流體輸送模組、一儲水槽、一設於該儲水槽底部的噴灑件及一控制模組,該流體輸送模組可受該控制模組的控制而將該容器內之該飲用水輸送至位於該容器頂部的該儲水槽中,該噴灑件可受該控制模組的控制而將該儲水槽內的該飲用水往下噴灑,使該容器內表面之該飲用水受到衝擊波動。 The second object of the present invention is to provide a hypoglycemic drinking and soothing system that can simulate the impact of water agitated by natural environment and effectively release various energy elements and vanadium elements. The technical means adopted to achieve the second object of the invention include a container, a hypoglycemic energy material, a base and an energy impact unit. The container can contain drinking water. The hypoglycemic energy material contains vanadium material with a weight ratio of about 2 to 15%, and the hypoglycemic energy material is immersed in drinking water in a container. The top of the base can be used for container placement. The energy impact unit is provided to stir and impact the drinking water, so that the hypoglycemic energy material can effectively release the vanadium element and the energy element from the drinking water under the stirring impact. Wherein, the energy impact unit further includes a fluid delivery module, a water storage tank, a spraying member provided at the bottom of the water storage tank, and a control module. The fluid delivery module can be controlled by the control module The drinking water in the container is delivered to the water storage tank at the top of the container, and the spraying member can be controlled by the control module to spray the drinking water in the water storage tank downward, so that the inner surface of the container Drinking water is subject to shocks.
10‧‧‧容器 10‧‧‧Container
11‧‧‧環緣 11‧‧‧Rim
12‧‧‧環體 12‧‧‧ring
13‧‧‧環片 13‧‧‧ring
130‧‧‧貫孔 130‧‧‧through hole
14‧‧‧環牆 14‧‧‧Circle Wall
140‧‧‧環形夾層 140‧‧‧Annular interlayer
20‧‧‧降血糖能量材料 20‧‧‧Lower blood sugar energy materials
30‧‧‧機座 30‧‧‧Base
40‧‧‧能量衝擊單元 40‧‧‧Energy impact unit
41‧‧‧傳動機構 41‧‧‧ Transmission mechanism
42‧‧‧攪動件 42‧‧‧Agitator
43‧‧‧流體輸送模組 43‧‧‧Fluid delivery module
44‧‧‧儲水槽 44‧‧‧Water storage tank
45‧‧‧噴灑件 45‧‧‧Spray parts
46‧‧‧控制模組 46‧‧‧Control module
47‧‧‧設定模組 47‧‧‧Setting module
48‧‧‧第一槽體 48‧‧‧The first tank
480‧‧‧第一穿孔 480‧‧‧First punch
49‧‧‧第二槽體 49‧‧‧Second tank
490‧‧‧第二穿孔 490‧‧‧Second Perforation
圖1係本發明第一實施例的實施示意圖。 FIG. 1 is an implementation schematic diagram of the first embodiment of the present invention.
圖2係本發明第二實施例的實施示意圖。 FIG. 2 is an implementation schematic diagram of a second embodiment of the present invention.
圖3係本發明第三實施例的實施的實施示意圖。 FIG. 3 is an implementation schematic diagram of the implementation of the third embodiment of the present invention.
圖4係本發明第二實施例的功能方塊控制示意圖 4 is a schematic diagram of function block control according to a second embodiment of the present invention
圖5係本發明第三實施例的功能方塊控制示意圖。 FIG. 5 is a schematic diagram of function block control according to a third embodiment of the present invention.
為讓 貴審查委員能進一步瞭解本發明整體的技術特徵與達成本發明目的之技術手段,玆以具體實施例並配合圖式加以詳細說明如下:請配合參看圖1~3所示為實現本發明第一目的之第一實 施例,係包括容器10、降血糖能量材料20、機座30及能量衝擊單元40等技術特徵。容器10可供飲用水容置其內。降血糖能量材料20至少包含佔重比約為2~15百分比的釩材料,降血糖能量材料20浸泡於容器10內的飲用水中。機座30頂部可供容器10置放。能量衝擊單元40用以對飲用水進行波動衝擊,使降血糖能量材料20在攪動衝擊下有效地將釩元素及能量元素釋出於飲用水之中。 In order for your reviewing committee to further understand the overall technical features of the present invention and the technical means to achieve the purpose of the invention, the specific embodiments and drawings are used to explain in detail as follows: Please refer to Figures 1 to 3 for the realization of the present invention The first embodiment of the first object includes technical features such as a
請配合參看圖2、5所示為實現本發明第二目的之第二實施例,係包括容器10、降血糖能量材料20、機座30及能量衝擊單元40等技術特徵。容器10可供飲用水容置其內。降血糖能量材料20包含佔重比約為2~15百分比的釩材料,降血糖能量材料20浸泡於容器10內的飲用水中。機座30頂部可供容器10置放。能量衝擊單元40用以對飲用水進行攪動衝擊,使降血糖能量材料20在攪動衝擊下有效地將釩元素及能量元素釋出於飲用水之中。其中,本發明主要在於,能量衝擊單元40係包含一傳動機構41、一攪動件42、一流體輸送模組43、一儲水槽44、一設於儲水槽44底部的噴灑件45及一控制模組46。攪動件42一端與傳動機構41連動,其反向之另端則伸入至容器10底部,可藉由傳動機構41的驅動使攪動件42以至少一個方向旋轉,以對液體進行至少一個方向轉動的攪動衝擊,使降血糖能量材料20可於飲用水中釋出釩元素及能量元素。流體輸送模組43可受控制模組46的控制而將容器10內之飲用水輸送至位於容器10頂部的儲水槽44中,噴灑件45可受控制模組46的控制而將儲水槽44內的飲用水往下噴灑衝擊,使容器10內表面之飲用水受到衝擊而產生震盪波動,於此,即可模擬水受到自然環境攪動衝擊而有效釋出各種能量元素及釩元素。另外,請參看圖4所示,控制模組46的動作控制時機,係預先由設定模組47 所加以設定,於此,得以實現使容器10內之飲用水達到攪動衝擊的效果。 Please refer to FIGS. 2 and 5 to illustrate the second embodiment of the second object of the present invention, which includes technical features such as a
再請配合參看圖1、2所示的實施例中,容器10內環設有一供一環體12定位其內的環緣11,環體12頂緣往圓心方向延伸有一環片13,此環片13中心貫穿設有一供攪動件42伸入的貫孔130,並於環片13環設有複數個第一鏤空部;環體12頂部外緣軸向延伸有一外徑較環體12為大的環牆14,此環牆14內部具有一相通的環形夾層140,此環形夾層140可供降血糖能量材料20容置其內,且環牆14之內外環面密佈有複數個第二鏤空部140。 With reference to the embodiments shown in FIGS. 1 and 2, the inner ring of the
請配合參看圖3、5所示,為實現本發明第二目的之第三實施例,上述能量衝擊單元40更包含一流體輸送模組43(包含管路及泵浦之組合)、一設於機座30頂部的第一槽體48、一設於機座30且位於第一槽體48下方的第二槽體49,及一控制模組46。容器10位於第二槽體49下方。第一槽體48密佈貫穿設有複數第一穿孔480。第二槽體49供容置降血糖能量材料20且貫穿設有第二穿孔490。流體輸送模組43可受控制模組46的控制而將容器10內之飲用水輸送至第一槽體48中,使飲用水可自各第一穿孔482流出並滴落位於第二槽體49內之降血糖能量材料20上,然後,再自第二穿孔490回流至容器10內,於此循環作用之下,即可使降血糖能量材料20可以受到滴落之飲用水的衝擊波動而不斷地釋出釩元素及多種能量元素。 Please refer to FIG. 3 and FIG. 5, in order to achieve the third embodiment of the second object of the present invention, the
進一步來說,本發明降血糖能量材料20可以是呈球狀;但是不以此為限,上述降血糖能量材料20除了包含佔重比約為2~15百分比的釩材料之外,更包含佔重比為5~10百分比的黏結劑、佔重比為40~70百分比的鹼土族(如鎂或鈣)以及佔重比為5~10百分比的電氣石粉末,經過製備 工序即可製成為球狀體結構形態。此外,上述電氣石粉末可以是電氣石粉末、遠紅外線陶瓷粉末或是鍺粉的其中一種。除此之外,本發明降血糖能量材料20亦可容設於一包覆殼內,此包覆殼係以一掛索固定在容器10內,於此,同樣可使降血糖能量材料20固定於容器10內,而達到浸泡與釋出微量元素與釩元素之保健與降血糖之效果。 Further, the
再者,由於上述降血糖能量材料20約有佔重比為40~70百分比的鹼土族(如鎂或鈣),因此,飲用水確實會含有奈米金屬鎂(即小分子團),進而產生負離子的負氫水(即水素水),可將飲用水瞬間負離子化;放射遠紅外線水活化,使水分子團變小,滲透力、擴散力、蠕動力、溶解力、代謝力都強於其他的水,通過細胞,則可促進人體的新陳代謝,排除有害酸性代謝物,抗人體衰老,可提高自身的免疫力;亦即,鎂+水=氧化鎂+氫氣Mg+2H2O==Mg(OH)2+H2。除此之外,此負氫水(即水素水)可藉由上述之攪動衝擊作用下而釋出上述的釩元素。 Furthermore, since the above-mentioned
在此必須說明的是,釩是一種礦物,釩確實是可以用於治療糖尿病、低血糖、高血脂、心臟疾病、結核病、梅毒等疾病。已有一些證據指出,釩可能像胰島素,或有助於增加胰島素的效應。釩是一種廣泛分佈自然界的過渡金屬元素,也是人體必需的微量元素。釩具有多種生物學功能,如調節碳水化合物的代謝,提高糖尿病患者的血糖穩定性等。依據醫學臨床報導指出,長期攝入低劑量的釩有利於糖尿病小鼠血糖的動態平衡,改善其葡萄糖耐量,換言之,成人在短期間內每日服用1.8mg(毫克)以下的釩並不會產生不適的副作用。 It must be noted here that vanadium is a mineral, and vanadium is indeed used to treat diseases such as diabetes, hypoglycemia, hyperlipidemia, heart disease, tuberculosis, and syphilis. There is some evidence that vanadium may be like insulin, or may help increase the effect of insulin. Vanadium is a widely distributed transition metal element in nature, and it is also an essential trace element for the human body. Vanadium has various biological functions, such as regulating the metabolism of carbohydrates and improving the stability of blood sugar in diabetic patients. According to medical clinical reports, long-term intake of low doses of vanadium is beneficial to the dynamic balance of blood glucose in diabetic mice and improves their glucose tolerance. In other words, adults taking less than 1.8 mg (mg) of vanadium per day for a short period of time will not produce Discomfort side effects.
釩在人體內含量極低,體內總量不足1mg,釩主要是分佈於內臟,尤其是肝、腎、甲狀腺等部位。人體對釩的正常需要量為100μg/d。 釩在胃腸吸收率僅5%,其吸收部位主要在上消化道。此外環境中的釩可經皮膚和肺吸收入體中。血液中約95%的釩以離子狀態(VO2+)與轉鐵蛋白結合而送輸,因此釩與鐵在體內可相互影響。釩對骨和牙齒正常發育及鈣化有關,能增強牙對齲牙的抵抗力。釩還可以促進糖代謝,刺激釩酸鹽依賴性NADPH氧化反應,增強脂酶活性,加快腺苷酸環化酶活化和氨基酸轉化及促進紅細胞生長等作用。釩在人體內含量極低,體內總量不足1mg。主要分佈於內臟,尤其是肝、腎、甲狀腺等部位,骨組織中含量也較高。人體對釩的正常需要量為100μg/d。釩在胃腸吸收率僅5%,其吸收部位主要在上消化道。此外環境中的釩可經皮膚和肺吸收入體中。血液中約95%的釩以離子狀態(VO2+)與轉鐵蛋白結合而送輸,因此釩與鐵在體內可相互影響。釩對骨和牙齒正常發育及鈣化有關,能增強牙對齲牙的抵抗力。釩還可以促進糖代謝,刺激釩酸鹽依賴性NADPH氧化反應,增強脂酶活性,加快腺苷酸環化酶活化和氨基酸轉化及促進紅細胞生長等作用。有實驗顯示,釩調節(Nak)-ATP酶、調節磷醯轉移酶、腺苷酸化酶、蛋白激酶類的輔因數,與體內激素,蛋白質,脂類代謝關係密切。 The content of vanadium in the human body is extremely low, and the total amount in the body is less than 1mg. Vanadium is mainly distributed in the internal organs, especially the liver, kidney, thyroid and other parts. The normal requirement of the human body for vanadium is 100 μg/d. The absorption rate of vanadium in the gastrointestinal tract is only 5%, and its absorption site is mainly in the upper digestive tract. In addition, vanadium in the environment can be absorbed into the body through the skin and lungs. Approximately 95% of vanadium in the blood is delivered in an ionic state (VO2+) combined with transferrin, so vanadium and iron can affect each other in the body. Vanadium is related to the normal development and calcification of bones and teeth, and can enhance the resistance of teeth to caries. Vanadium can also promote sugar metabolism, stimulate vanadate-dependent NADPH oxidation, enhance lipase activity, accelerate adenylate cyclase activation and amino acid conversion, and promote red blood cell growth. The content of vanadium in the human body is extremely low, and the total amount in the body is less than 1 mg. Mainly distributed in the internal organs, especially the liver, kidney, thyroid and other parts, the bone tissue content is also high. The normal requirement of the human body for vanadium is 100 μg/d. The absorption rate of vanadium in the gastrointestinal tract is only 5%, and its absorption site is mainly in the upper digestive tract. In addition, vanadium in the environment can be absorbed into the body through the skin and lungs. Approximately 95% of vanadium in the blood is delivered in an ionic state (VO2+) combined with transferrin, so vanadium and iron can affect each other in the body. Vanadium is related to the normal development and calcification of bones and teeth, and can enhance the resistance of teeth to caries. Vanadium can also promote sugar metabolism, stimulate vanadate-dependent NADPH oxidation, enhance lipase activity, accelerate adenylate cyclase activation and amino acid conversion, and promote red blood cell growth. Experiments have shown that vanadium-regulated (Nak)-ATPase, cofactors that regulate phosphotransferase, adenylase, and protein kinases are closely related to hormone, protein, and lipid metabolism in the body.
由上述得知,釩確實是人體不可或缺的元素之一,由於本發明係採用浸泡衝擊方式使釩元素釋出,所以就算是飲用大量本發明所製備含釩飲用水,進入體內的釩元素劑量也不會超過1.8mg(毫克)的服用上限,於此,即可有效降低糖尿病病患的血糖,進而達到舒緩糖尿病的不適症狀之目的。 From the above, vanadium is indeed one of the indispensable elements of the human body. Since the present invention uses the immersion impact method to release the vanadium element, even if drinking a large amount of vanadium-containing drinking water prepared by the present invention, the vanadium element entering the body The dose will not exceed the upper limit of 1.8mg (mg), which can effectively reduce the blood sugar of diabetic patients, and then achieve the purpose of alleviating the discomfort symptoms of diabetes.
以上所述,僅為本發明之可行實施例,並非用以限定本發明之專利範圍,凡舉依據下列請求項所述之內容、特徵以及其精神而為之其 他變化的等效實施,皆應包含於本發明之專利範圍內。本發明所具體界定於請求項之結構特徵,未見於同類物品,且具實用性與進步性,已符合發明專利要件,爰依法具文提出申請,謹請 鈞局依法核予專利,以維護本申請人合法之權益。 The above is only a feasible embodiment of the present invention and is not intended to limit the patent scope of the present invention. Any equivalent implementation of other changes based on the content, features and spirit described in the following claims should be Included in the patent scope of the present invention. The structural features of the invention specifically defined in the claim are not found in similar items, and are practical and progressive. They have met the requirements of the invention patent. You have filed an application in accordance with the law, and I would like to ask the Jun Bureau to approve the patent in accordance with the law to maintain this. The applicant's legal rights and interests.
10‧‧‧容器 10‧‧‧Container
11‧‧‧環緣 11‧‧‧Rim
12‧‧‧環體 12‧‧‧ring
13‧‧‧環片 13‧‧‧ring
130‧‧‧貫孔 130‧‧‧through hole
14‧‧‧環牆 14‧‧‧Circle Wall
140‧‧‧環形夾層 140‧‧‧Annular interlayer
20‧‧‧降血糖能量材料 20‧‧‧Lower blood sugar energy materials
30‧‧‧機座 30‧‧‧Base
40‧‧‧能量衝擊單元 40‧‧‧Energy impact unit
41‧‧‧傳動機構 41‧‧‧ Transmission mechanism
42‧‧‧攪動件 42‧‧‧Agitator
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW106113286A TWI692448B (en) | 2017-04-20 | 2017-04-20 | Drinking and soothing system for lowering blood sugar |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW106113286A TWI692448B (en) | 2017-04-20 | 2017-04-20 | Drinking and soothing system for lowering blood sugar |
Publications (2)
Publication Number | Publication Date |
---|---|
TW201838931A TW201838931A (en) | 2018-11-01 |
TWI692448B true TWI692448B (en) | 2020-05-01 |
Family
ID=65033793
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW106113286A TWI692448B (en) | 2017-04-20 | 2017-04-20 | Drinking and soothing system for lowering blood sugar |
Country Status (1)
Country | Link |
---|---|
TW (1) | TWI692448B (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1927222A (en) * | 2006-08-28 | 2007-03-14 | 浙江大学 | Vanadium tonic comprising anion exchange resin as carrier, their preparation method and uses |
JP2007526327A (en) * | 2004-03-01 | 2007-09-13 | ウェルネス エンタープライゼス エルエルシー | How to use enhanced water to improve glycemic control |
-
2017
- 2017-04-20 TW TW106113286A patent/TWI692448B/en not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007526327A (en) * | 2004-03-01 | 2007-09-13 | ウェルネス エンタープライゼス エルエルシー | How to use enhanced water to improve glycemic control |
CN1927222A (en) * | 2006-08-28 | 2007-03-14 | 浙江大学 | Vanadium tonic comprising anion exchange resin as carrier, their preparation method and uses |
Also Published As
Publication number | Publication date |
---|---|
TW201838931A (en) | 2018-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101036770A (en) | External emplastrum for treating deficiency-cold for children | |
CN102225139A (en) | Chenshu invigorating spleen paste and its preparation method | |
TWI692448B (en) | Drinking and soothing system for lowering blood sugar | |
Asnani et al. | Is weight loss possible in patients treated with thiazolidinediones? Experience with a low-calorie diet | |
CN106418398A (en) | Food for treating diabetes | |
CN103071129A (en) | Chinese patent drug for curing vomit | |
CN102125094B (en) | Yogurt beverage capable of preventing and treating astriction and preparation method | |
CN104001003A (en) | Oral liquid and sublingual spraying agent for treating diabetes | |
CN102068680B (en) | Omphaloidean external medicament for treating enteritis and preparation method thereof | |
CN108261487A (en) | A kind of analgesia Chinese medicine composition and its obtained analgesia ointment and pain easing plaster | |
CN105343419A (en) | Traditional Chinese medicinal pill for invigorating yang and tonifying kidney, and preparation method thereof | |
CN101085073A (en) | Mulberry leaves and almond oral liquid | |
CN1966044A (en) | Capsule for treating disease caused by emotional disorder | |
CN1279955C (en) | Medicine tea for curing diabetes | |
CN1557301A (en) | Compositions for senile diabetes patient blood sugar and blood fat reduction | |
KR20190011975A (en) | A healthcare method used water vitality energy | |
CN101653495B (en) | Chinese traditional medicine for curing insomnia | |
CN102058862A (en) | Externally applied medicament for pediatric umbilical part and preparation method thereof | |
CN1557292A (en) | Formulation for improving human growth hormone release and its uses | |
CN101468071B (en) | Chinese medicine medicine for suppressing and alleviating sex urge for male and female | |
CN106038926A (en) | Traditional Chinese medicine for treating diabetes and preparation method thereof | |
Bingham et al. | Combined insulin-sulfonylurea treatment of type II diabetes | |
CN1111426C (en) | Diabetes treating medicine | |
CN1354002A (en) | Medicine for curing gastrointestinal diseases and its production method | |
CN108853378A (en) | A kind for the treatment of diabetes formula and preparation method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |